{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:27:05Z","timestamp":1781249225700,"version":"3.54.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>Dyslipidemia is a major risk factor for the development of cardiovascular disease. Both statins and omega-3 fatty acids demonstrate beneficial effects on lipid concentrations. The goal was to evaluate the safety and efficacy of combination therapy with statins and omega-3 fatty acids.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We performed a systematic review and meta-analysis of published data to compare the safety and efficacy of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia. Six articles were assessed in the present meta-analysis (quantitative assessment) and qualitative assessment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In terms of efficacy, the combination treatment afforded a significantly greater reduction in total cholesterol\/high-density lipoprotein cholesterol than statin alone did [standard difference in means\u200a=\u200a\u22120.215; 95% confidence interval (CI) \u22120.359\u2013\u22120.071]. However, there was no significant difference in low-density lipoprotein (LDL) cholesterol between the 2 groups. Qualitative assessment of other lipid parameters was performed. Combination therapy with statins and omega-3 fatty acids was generally more effective on lipid concentration than statin monotherapy. In terms of safety, there were no significant differences in total adverse events between the 2 groups. Gastrointestinal adverse events were found to be significantly increased in patients receiving combination therapy using the fixed-effects model (relative risk\u200a=\u200a0.547; 95% CI 0.368\u20130.812).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>We suggest that combination therapy with statins and omega-3 fatty acids enhances lipid profile, except LDL cholesterol, compared with statin monotherapy. Nevertheless, statin and omega-3 fatty acid combination should be cautiously recommended, taking into account the clinical importance of LDL cholesterol and safety issues associated with their concomitant use.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013593","type":"journal-article","created":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T02:51:23Z","timestamp":1544842283000},"page":"e13593","source":"Crossref","is-referenced-by-count":24,"title":["Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia"],"prefix":"10.1097","volume":"97","author":[{"given":"Hye Duck","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Min","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/01.ATV.9.1.58","article-title":"Dietary fish oil increases conversion of very low density lipoprotein apo B to low density lipoprotein","volume":"9","author":"Huff","year":"1989","journal-title":"Arteriosclerosis"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0021-9150(99)00267-1","article-title":"Omacor in familial combined hyperlipidemia: effects on lipids and low-density lipoprotein subclasses","volume":"148","author":"Calabresi","year":"2000","journal-title":"Atherosclerosis"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/ajcn\/77.2.300","article-title":"Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity","volume":"77","author":"Chan","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0021-9150(86)90072-9","article-title":"Paradoxical elevation of LDL apoprotein B levels in hypertriglyceridemic patients and normal subjects ingesting fish oil","volume":"61","author":"Sullivan","year":"1986","journal-title":"Atherosclerosis"},{"issue":"(5 suppl)","key":"R6-20230914","doi-asserted-by":"crossref","first-page":"1645S","DOI":"10.1093\/ajcn\/65.5.1645S","article-title":"N-3 fatty acids and serum lipoproteins: human studies","volume":"65","author":"Harris","year":"1997","journal-title":"Am J Clin Nutr"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinthera.2007.07.018","article-title":"Efficacy and tolerability of adding prescription omega-3 fatty acids 4\u200ag\/d to simvastatin 40\u200amg\/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study","volume":"29","author":"Davidson","year":"2007","journal-title":"Clin Ther"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.amjcard.2008.03.078","article-title":"Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20\u200amg\/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia","volume":"102","author":"Maki","year":"2008","journal-title":"Am J Cardiol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jacl.2008.12.007","article-title":"Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80\u200amg: effects in mixed dyslipidemia","volume":"3","author":"Maki","year":"2009","journal-title":"J Clin Lipidol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4065\/mcp.2009.0397","article-title":"Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin","volume":"85","author":"Bays","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"1400.e1-3","DOI":"10.1016\/j.clinthera.2013.07.420","article-title":"A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial)","volume":"35","author":"Maki","year":"2013","journal-title":"Clin Ther"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am J Cardiol"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"R15-20230914","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective sties of diseases","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometircs"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00043798-199602000-00010","article-title":"Comparison of multivariate predictive power of major risk factors for coronary heart diseases in different countries: results from eight nations of the Seven Countries Study, 25-year follow-up","volume":"3","author":"Menotti","year":"1996","journal-title":"J Cardiovasc risk"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1161\/01.CIR.103.17.2213","article-title":"Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report","volume":"103","author":"Gotto","year":"2001","journal-title":"Circulation"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1097\/MJT.0000000000000048","article-title":"Statin use mitigate the benefit of omega-3 fatty acids supplementation-A meta-regression of randomized trials","volume":"23","author":"Sethi","year":"2016","journal-title":"Am J Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201812140-00069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T21:06:16Z","timestamp":1694725576000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201812140-00069"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":22,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013593","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}